These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 38578902)

  • 1. Twelve Years of Drug Prioritization to Help Accelerate Disease Modification Trials in Parkinson's Disease: The International Linked Clinical Trials Initiative.
    Wyse RK; Isaacs T; Barker RA; Cookson MR; Dawson TM; Devos D; Dexter DT; Duffen J; Federoff H; Fiske B; Foltynie T; Fox S; Greenamyre JT; Kieburtz K; Kordower JH; Krainc D; Matthews H; Moore DJ; Mursaleen L; Schwarzschild MA; Stott SRW; Sulzer D; Svenningsson P; Tanner CM; Carroll C; Simon DK; Brundin P
    J Parkinsons Dis; 2024; 14(4):657-666. PubMed ID: 38578902
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Linked clinical trials--the development of new clinical learning studies in Parkinson's disease using screening of multiple prospective new treatments.
    Brundin P; Barker RA; Conn PJ; Dawson TM; Kieburtz K; Lees AJ; Schwarzschild MA; Tanner CM; Isaacs T; Duffen J; Matthews H; Wyse RK
    J Parkinsons Dis; 2013 Jan; 3(3):231-9. PubMed ID: 24018336
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Linked Clinical Trials initiative (LCT) for Parkinson's disease.
    Brundin P; Wyse RK
    Eur J Neurosci; 2019 Feb; 49(3):307-315. PubMed ID: 30269406
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Parkinson's Disease Drug Therapies in the Clinical Trial Pipeline: 2020.
    McFarthing K; Buff S; Rafaloff G; Dominey T; Wyse RK; Stott SRW
    J Parkinsons Dis; 2020; 10(3):757-774. PubMed ID: 32741777
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Parkinson's Disease Drug Therapies in the Clinical Trial Pipeline: 2021 Update.
    McFarthing K; Rafaloff G; Baptista MAS; Wyse RK; Stott SRW
    J Parkinsons Dis; 2021; 11(3):891-903. PubMed ID: 34151864
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disease-modifying strategies for Parkinson's disease.
    Kalia LV; Kalia SK; Lang AE
    Mov Disord; 2015 Sep; 30(11):1442-50. PubMed ID: 26208210
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug Repurposing for Parkinson's Disease: The International Linked Clinical Trials experience.
    Stott SRW; Wyse RK; Brundin P
    Front Neurosci; 2021; 15():653377. PubMed ID: 33815053
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Parkinson's Disease Drug Therapies in the Clinical Trial Pipeline: 2022 Update.
    McFarthing K; Rafaloff G; Baptista M; Mursaleen L; Fuest R; Wyse RK; Stott SRW
    J Parkinsons Dis; 2022; 12(4):1073-1082. PubMed ID: 35527571
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disease-Modifying Drugs in Parkinson's Disease.
    Park A; Stacy M
    Drugs; 2015 Dec; 75(18):2065-71. PubMed ID: 26581672
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Approaches to Disease Modification for Parkinson's Disease: Clinical Trials and Lessons Learned.
    Hung AY; Schwarzschild MA
    Neurotherapeutics; 2020 Oct; 17(4):1393-1405. PubMed ID: 33205384
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The evidence for disease modification in Parkinson's disease.
    Lew MF
    Int J Neurosci; 2011; 121 Suppl 2():18-26. PubMed ID: 22035026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug Repurposing in Parkinson's Disease.
    Athauda D; Foltynie T
    CNS Drugs; 2018 Aug; 32(8):747-761. PubMed ID: 30066310
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disease Modification in Parkinson's Disease: Current Approaches, Challenges, and Future Considerations.
    Lang AE; Espay AJ
    Mov Disord; 2018 May; 33(5):660-677. PubMed ID: 29644751
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A review of clinical trial designs used to detect a disease-modifying effect of drug therapy in Alzheimer's disease and Parkinson's disease.
    McGhee DJ; Ritchie CW; Zajicek JP; Counsell CE
    BMC Neurol; 2016 Jun; 16():92. PubMed ID: 27312378
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Simvastatin as a Potential Disease-Modifying Therapy for Patients with Parkinson's Disease: Rationale for Clinical Trial, and Current Progress.
    Carroll CB; Wyse RKH
    J Parkinsons Dis; 2017; 7(4):545-568. PubMed ID: 29036837
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disease modification in Parkinson's disease.
    Henchcliffe C; Severt WL
    Drugs Aging; 2011 Aug; 28(8):605-15. PubMed ID: 21812497
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simvastatin as a neuroprotective treatment for Parkinson's disease (PD STAT): protocol for a double-blind, randomised, placebo-controlled futility study.
    Carroll CB; Webb D; Stevens KN; Vickery J; Eyre V; Ball S; Wyse R; Webber M; Foggo A; Zajicek J; Whone A; Creanor S
    BMJ Open; 2019 Oct; 9(10):e029740. PubMed ID: 31594876
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interpreting the results of Parkinson's disease clinical trials: time for a change.
    Holford NH; Nutt JG
    Mov Disord; 2011 Mar; 26(4):569-77. PubMed ID: 21370266
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New hopes for disease modification in Parkinson's Disease.
    Poewe W; Seppi K; Marini K; Mahlknecht P
    Neuropharmacology; 2020 Jul; 171():108085. PubMed ID: 32298705
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advances in drug development for Parkinson's disease: present status.
    Harikrishna Reddy D; Misra S; Medhi B
    Pharmacology; 2014; 93(5-6):260-71. PubMed ID: 25096413
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.